- Home
- ELDN vs BDTX Comparison
ELDN vs BDTX Comparison
Compare ELDN & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- BDTX
- Stock Information
- Founded
- ELDN 2004
- BDTX 2014
- Country
- ELDN United States
- BDTX United States
- Employees
- ELDN N/A
- BDTX N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELDN Health Care
- BDTX Health Care
- Exchange
- ELDN Nasdaq
- BDTX Nasdaq
- Market Cap
- ELDN 202.4M
- BDTX 181.4M
- IPO Year
- ELDN N/A
- BDTX 2020
- Fundamental
- Price
- ELDN $2.73
- BDTX $3.90
- Analyst Decision
- ELDN Strong Buy
- BDTX Strong Buy
- Analyst Count
- ELDN 2
- BDTX 5
- Target Price
- ELDN $12.50
- BDTX $12.00
- AVG Volume (30 Days)
- ELDN 998.5K
- BDTX 1.0M
- Earning Date
- ELDN 11-11-2025
- BDTX 11-04-2025
- Dividend Yield
- ELDN N/A
- BDTX N/A
- EPS Growth
- ELDN N/A
- BDTX N/A
- EPS
- ELDN 0.21
- BDTX 0.25
- Revenue
- ELDN N/A
- BDTX $70,000,000.00
- Revenue This Year
- ELDN N/A
- BDTX N/A
- Revenue Next Year
- ELDN N/A
- BDTX N/A
- P/E Ratio
- ELDN $12.80
- BDTX $15.62
- Revenue Growth
- ELDN N/A
- BDTX N/A
- 52 Week Low
- ELDN $2.32
- BDTX $1.20
- 52 Week High
- ELDN $5.54
- BDTX $4.03
- Technical
- Relative Strength Index (RSI)
- ELDN 54.22
- BDTX 68.52
- Support Level
- ELDN $2.48
- BDTX $3.62
- Resistance Level
- ELDN $2.71
- BDTX $4.03
- Average True Range (ATR)
- ELDN 0.17
- BDTX 0.21
- MACD
- ELDN 0.04
- BDTX 0.05
- Stochastic Oscillator
- ELDN 60.95
- BDTX 86.63
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.